Mark GuerinChief Financial Officer at Onconova Therapeutics, Inc.
Mr. Guerin joined Onconova Therapeutics in September 2013 to augment the financial reporting, forecasting, and internal controls capabilities of the company following the IPO in July 2013, and was named Chief Financial Officer in 2016. During his tenure as CFO, Onconova has completed several financing transactions, including a rights offering, public offerings, registered direct offerings, and at-the-market offerings. Prior to joining Onconova, Mr. Guerin worked as an interim senior finance & accounting executive facilitating the post-acquisition integration activities of newly-acquired private equity portfolio companies. Previously, Mr. Guerin was the VP Finance & CFO of Cardiokine, Inc. through that company’s filing of a New Drug Application and the sale of the company. Prior to joining Cardiokine, Mr. Guerin was Director, Financial Reporting & Internal Controls at Barrier Therapeutics, Inc. during Barrier’s IPO and follow-on offering. Mr. Guerin started his career at Coopers & Lybrand in Philadelphia. He received his bachelor’s degree in Accounting from DeSales University and has earned the CPA, CMA, CGMA, and CFM professional certifications.